Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Immucell (ICCC) Accounts Payables (2016 - 2025)

Historic Accounts Payables for Immucell (ICCC) over the last 16 years, with Q3 2025 value amounting to $2.3 million.

  • Immucell's Accounts Payables fell 722.39% to $2.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $2.3 million, marking a year-over-year decrease of 722.39%. This contributed to the annual value of $2.5 million for FY2024, which is 1686.1% up from last year.
  • According to the latest figures from Q3 2025, Immucell's Accounts Payables is $2.3 million, which was down 722.39% from $2.6 million recorded in Q2 2025.
  • Immucell's Accounts Payables' 5-year high stood at $2.6 million during Q2 2025, with a 5-year trough of $1.2 million in Q2 2021.
  • In the last 5 years, Immucell's Accounts Payables had a median value of $2.0 million in 2025 and averaged $1.9 million.
  • In the last 5 years, Immucell's Accounts Payables surged by 4330.3% in 2022 and then tumbled by 813.37% in 2025.
  • Over the past 5 years, Immucell's Accounts Payables (Quarter) stood at $1.6 million in 2021, then grew by 23.95% to $2.0 million in 2022, then grew by 6.17% to $2.1 million in 2023, then increased by 16.86% to $2.5 million in 2024, then fell by 6.4% to $2.3 million in 2025.
  • Its Accounts Payables stands at $2.3 million for Q3 2025, versus $2.6 million for Q2 2025 and $2.0 million for Q1 2025.